About: Calling for an exponential escalation scheme in vaccine development for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Calling for an exponential escalation scheme in vaccine development for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Calling for an exponential escalation scheme in vaccine development for COVID-19
Creator	Wehling, Martin
Source	Medline; PMC
abstract	PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines. METHODS: Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. RESULTS: Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. CONCLUSION: A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1007/s00228-020-02933-w
bibo:pmid	32548679
has license	no-cc
sha1sum (hex)	d6aec40514fca0dd214db8b7f87d96c1ad51d66f
schema:url	https://doi.org/10.1007/s00228-020-02933-w
resource representing a document's title	Calling for an exponential escalation scheme in vaccine development for COVID-19
has PubMed Central identifier	PMC7297510
has PubMed identifier	32548679
schema:publication	Eur J Clin Pharmacol
resource representing a document's body	covid:d6aec40514fca0dd214db8b7f87d96c1ad51d66f#body_text
is schema:about of	named entity 'development' covid:arg/d6aec40514fca0dd214db8b7f87d96c1ad51d66f named entity 'Results' named entity 'antibody' named entity 'risk' named entity 'calls' named entity 'safety' named entity 'rapidly' named entity 'antibody' named entity 'vaccines' named entity 'tenfold' named entity 'COVID-19' named entity 'exponentially' named entity 'pandemic' named entity 'vaccines' named entity 'vaccines' named entity 'vaccinating' named entity 'clinical pharmacologist' named entity 'vaccine studies' named entity '12 weeks' named entity 'vaccination' named entity 'rule of thumb' named entity 'antibody response' named entity 'vaccines' named entity 'vaccine' named entity 'Vaccination' named entity 'antibody response' named entity 'neutralizing antibodies' named entity 'phase 1' named entity 'animal testing' named entity 'live-attenuated' named entity 'infection' named entity 'antibody-dependent enhancement' named entity 'vaccine' named entity 'vaccine' named entity 'Vaccine' named entity 'homologies' named entity 'antibody' named entity 'receptor' named entity 'protein' named entity 'medical care' named entity 'placebo group' named entity 'Brazil' named entity 'clinical trials' named entity 'antibody' named entity 'clinical testing' named entity 'infection' named entity 'health care' named entity 'influenza vaccine' named entity 'COVID-19' named entity 'hypocretin' named entity 'vaccine' named entity '12 weeks' named entity 'vaccine' named entity 'vaccination' named entity 'human trials' named entity 'vaccines' named entity '1,000,000' named entity 'COVID-19' named entity 'COVID-19' named entity '100 million' named entity 'antibody' named entity 'clinical trials' named entity 'Pandemrix' named entity 'vaccine' named entity 'clinical development' named entity 'antibodies' named entity 'homology' named entity 'infection' named entity 'vaccine' named entity 'vaccination' named entity 'COVID-19' named entity 'supply' named entity 'vaccine' named entity 'vaccine' named entity 'COVID-19 vaccine' named entity 'phase 1' named entity 'number' named entity 'COVID-19' named entity 'vaccination' named entity 'vaccinated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software